Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company.
Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.